Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Duell

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Haematologica|August 30, 2023
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND studyJohannes Duell, Pau Abrisqueta, Marc Andre, et al.
The Lancet. Oncology|June 9, 2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 studyGilles Salles, Johannes Duell, Eva González Barca, et al.
Nuklearmedizin. Nuclear Medicine|January 8, 2024
CXCR4-targeted Theranostics in Hematooncology: Opportunities and ChallengesRudolf Werner, Alexander Haug, Christian Buske, et al.
Blood|November 17, 2023
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapyJohannes Duell, Alexander M Leipold, Silke Appenzeller, et al.
Blood|June 27, 2023
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND studyDavid Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, et al.
Blood|August 23, 2017
Hematopoietic stem cell involvement in <i>BCR-ABL1-</i>positive ALL as a potential mechanism of resistance to blinatumomab therapyInga Nagel, Marius Bartels, Johannes Duell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone LymphomaJohannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Blood Advances|September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MMMarietta S Truger, Johannes Duell, Xiang Zhou, et al.
Journal for Immunotherapy of Cancer|March 22, 2024
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphomaJurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, et al.
Haematologica|August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Haematologica|August 30, 2023
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND studyJohannes Duell, Pau Abrisqueta, Marc Andre, et al.
The Lancet. Oncology|June 9, 2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 studyGilles Salles, Johannes Duell, Eva González Barca, et al.
Nuklearmedizin. Nuclear Medicine|January 8, 2024
CXCR4-targeted Theranostics in Hematooncology: Opportunities and ChallengesRudolf Werner, Alexander Haug, Christian Buske, et al.
Blood|November 17, 2023
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapyJohannes Duell, Alexander M Leipold, Silke Appenzeller, et al.
Blood|June 27, 2023
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND studyDavid Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, et al.
Blood|August 23, 2017
Hematopoietic stem cell involvement in <i>BCR-ABL1-</i>positive ALL as a potential mechanism of resistance to blinatumomab therapyInga Nagel, Marius Bartels, Johannes Duell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone LymphomaJohannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Blood Advances|September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MMMarietta S Truger, Johannes Duell, Xiang Zhou, et al.
Journal for Immunotherapy of Cancer|March 22, 2024
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphomaJurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, et al.
Haematologica|August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Pageof 5